Follistatin

✓Key benefits

📈What to expect

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Overview

Follistatin is a single-chain glycoprotein produced in nearly all tissues, with the highest concentrations in ovarian follicular fluid where it was first identified. Its primary role is binding and inhibiting activin and myostatin - two members of the TGF-beta superfamily that limit muscle growth. Follistatin 344 (FS-344) is the most commonly referenced isoform in the peptide community. Animal studies, particularly the famous 'mighty mouse' experiments, demonstrated that follistatin overexpression can double muscle mass without exercise. While the human picture is more nuanced, follistatin remains one of the most discussed peptides for body composition.

⚙️How it works

Follistatin binds directly to myostatin (GDF-8) and activin A, preventing them from signalling through their receptors. Myostatin normally acts as a brake on muscle growth by inhibiting satellite cell proliferation and protein synthesis. By neutralising this brake, follistatin shifts the balance toward muscle hypertrophy and hyperplasia. It also influences follicle-stimulating hormone (FSH) regulation, fat metabolism, and has shown anti-fibrotic properties in preclinical models.

⚡Side effects

📅Research history

The myostatin connection

Myostatin was discovered in 1997 when Se-Jin Lee at Johns Hopkins showed that mice lacking the myostatin gene developed roughly twice the normal muscle mass. Since then, naturally occurring myostatin mutations have been documented in cattle (Belgian Blue breed), dogs (whippets), and at least one human child. Follistatin became a target because it is the body's natural myostatin inhibitor. The challenge with synthetic follistatin peptide is that injectable forms have a short half-life, and the dramatic results seen in gene therapy and knockout models have not been replicated with peptide administration at practical doses.

Gene therapy vs peptide form

Most of the dramatic follistatin results come from gene therapy studies, where AAV vectors deliver the follistatin gene directly into muscle tissue for sustained expression. Nationwide Children's Hospital has conducted clinical trials using follistatin gene therapy for Becker muscular dystrophy with measurable improvements in the 6-minute walk test. The injectable peptide form, while popular in the biohacking community, produces more modest effects due to its short circulating half-life. Users should set expectations accordingly.

References

1. [1]Rodino-Klapac LR, et al. 'Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.' Muscle & Nerve, 2009.
2. [2]Mendell JR, et al. 'Follistatin gene therapy for Becker muscular dystrophy.' Molecular Therapy, 2015.

Frequently asked questions

Related peptides